Programmable Delivery of Synergistic Cancer Drug Combinations Using Bicompartmental Nanoparticles

被引:13
作者
Gregory, Jason V. [1 ,2 ]
Vogus, Douglas R. [3 ]
Barajas, Alexandra [4 ]
Cadena, Melissa A. [5 ]
Mitragotri, Samir [3 ]
Lahann, Joerg [1 ,2 ,5 ]
机构
[1] Univ Michigan, Biointerfaces Inst, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Chem Engn, Ann Arbor, MI 48109 USA
[3] Harvard Univ, John A Paulson Sch Engn & Appl Sci, Cambridge, MA 02138 USA
[4] Univ Calif Santa Barbara, Dept Chem Engn, Santa Barbara, CA 93106 USA
[5] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA
基金
美国国家科学基金会;
关键词
cancer; combination therapy; drug delivery; nanomedicine; nanoparticles; CO-DELIVERY; MULTIDRUG-RESISTANCE; ACETALATED DEXTRAN; 1ST-LINE TREATMENT; IN-VITRO; LAPATINIB; PACLITAXEL; SYSTEM; PARTICLES; RELEASE;
D O I
10.1002/adhm.202000564
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Delivery of multiple therapeutics has become a preferred method of treating cancer, albeit differences in the biodistribution and pharmacokinetic profiles of individual drugs pose challenges in effectively delivering synergistic drug combinations to and at the tumor site. Here, bicompartmental Janus nanoparticles comprised of domains are reported with distinct bulk properties that allow for independent drug loading and release. Programmable drug release can be triggered by a change in the pH value and depends upon the bulk properties of the polymers used in the respective compartments, rather than the molecular structures of the active agents. Bicompartmental nanoparticles delivering a synergistic combination of lapatinib and paclitaxel result in increased activity against HER2+ breast cancer cells. Surprisingly, the dual drug loaded particles also show significant efficacy toward triple negative breast cancer, even though this cancer model is unresponsive to lapatinib alone. The broad versatility of the nanoparticle platform allows for rapid exploration of a wide range of drug combinations where both their relative drug ratios and temporal release profiles can be optimized.
引用
收藏
页数:11
相关论文
共 54 条
  • [1] [Anonymous], 2017, BRIEFINGS BIOINF
  • [2] Acetal-derivatized dextran:: An acid-responsive biodegradable material for therapeutic applications
    Bachelder, Eric M.
    Beaudette, Tristan T.
    Broaders, Kyle E.
    Dashe, Jesse
    Frechet, Jean M. J.
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2008, 130 (32) : 10494 - +
  • [3] Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
    Baselga, Jose
    Bradbury, Ian
    Eidtmann, Holger
    Di Cosimo, Serena
    de Azambuja, Evandro
    Aura, Claudia
    Gomez, Henry
    Dinh, Phuong
    Fauria, Karine
    Van Dooren, Veerle
    Aktan, Gursel
    Goldhirsch, Aron
    Chang, Tsai-Wang
    Horvath, Zsolt
    Coccia-Portugal, Maria
    Domont, Julien
    Tseng, Ling-Min
    Kunz, Georg
    Sohn, Joo Hyuk
    Semiglazov, Vladimir
    Lerzo, Guillermo
    Palacova, Marketa
    Probachai, Volodymyr
    Pusztai, Lajos
    Untch, Michael
    Gelber, Richard D.
    Piccart-Gebhart, Martine
    [J]. LANCET, 2012, 379 (9816) : 633 - 640
  • [4] Electrospun Acetalated Dextran Scaffolds for Temporal Release of Therapeutics
    Borteh, Hassan M.
    Gallovic, Matthew D.
    Sharma, Sadhana
    Peine, Kevin J.
    Miao, Simeng
    Brackman, Deanna J.
    Gregg, Katie
    Xu, Yanyi
    Guo, Xiaolei
    Guan, Jianjun
    Bachelder, Eric M.
    Ainslie, Kristy M.
    [J]. LANGMUIR, 2013, 29 (25) : 7957 - 7965
  • [5] Red blood cell-hitchhiking boosts delivery of nanocarriers to chosen organs by orders of magnitude
    Brenner, Jacob S.
    Pan, Daniel C.
    Myerson, Jacob W.
    Marcos-Contreras, Oscar A.
    Villa, Carlos H.
    Patel, Priyal
    Hekierski, Hugh
    Chatterjee, Shampa
    Tao, Jian-Qin
    Parhiz, Hamideh
    Bhamidipati, Kartik
    Uhler, Thomas G.
    Hood, Elizabeth D.
    Kiseleva, Raisa Yu.
    Shuvaev, Vladimir S.
    Shuvaeva, Tea
    Khoshnejad, Makan
    Johnston, Ian
    Gregory, Jason V.
    Lahann, Joerg
    Wang, Tao
    Cantu, Edward
    Armstead, William M.
    Mitragotri, Samir
    Muzykantov, Vladimir
    [J]. NATURE COMMUNICATIONS, 2018, 9
  • [6] Acetalated dextran is a chemically and biologically tunable material for particulate immunotherapy
    Broaders, Kyle E.
    Cohen, Joel A.
    Beaudette, Tristan T.
    Bachelder, Eric M.
    Frechet, Jean M. J.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (14) : 5497 - 5502
  • [7] Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges
    Butti, Ramesh
    Das, Sumit
    Gunasekaran, Vinoth Prasanna
    Yadav, Amit Singh
    Kumar, Dhiraj
    Kundu, Gopal C.
    [J]. MOLECULAR CANCER, 2018, 17
  • [8] A Phase I Study of a 2-Day Lapatinib Chemosensitization Pulse Preceding Nanoparticle Albumin-Bound Paclitaxel for Advanced Solid Malignancies
    Chien, Amy J.
    Illi, Julie A.
    Ko, Andrew H.
    Korn, Wolfgang M.
    Fong, Lawrence
    Chen, Lee-may
    Kashani-Sabet, Mohammed
    Ryan, Charles J.
    Rosenberg, Jonathan E.
    Dubey, Sarita
    Small, Eric J.
    Jahan, Thierry M.
    Hylton, Nola M.
    Yeh, Benjamin M.
    Huang, Yong
    Koch, Kevin M.
    Moasser, Mark M.
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (17) : 5569 - 5575
  • [9] QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS
    CHOU, TC
    TALALAY, P
    [J]. ADVANCES IN ENZYME REGULATION, 1984, 22 : 27 - 55
  • [10] In vitro and in vivo evaluation of paclitaxel-lapatinib-loaded F127 pluronic micelles
    Dehghankelishadi, Pouya
    Saadat, Ebrahim
    Ravar, Fatemeh
    Safavi, Maliheh
    Pordeli, Mahboobeh
    Gholami, Mehdi
    Dorkoosh, Farid Abedin
    [J]. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2017, 43 (03) : 390 - 398